ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The U.S. Food and Drug Administration recently awarded ZetaMet™ Breakthrough Device Designation for the treatment of metastatic bone cancer. Currently, ZetaMet™ is being reviewed by the FDA and Health Canada for a human clinical study for patients living with metastatic breast cancer. Enrollment for this study could begin late Q4-2021.
ZetaMet Flowable™, administered via a minimally-invasive percutaneous outpatient procedure, is designed for the treatment of patients with metastatic lesions that have or will result in a Skeletal-Related events (SREs) including fractures and spinal cord compression.
ZetaFuse™ is the first synthetic, small molecule, osteo-inductive biologic, to safely aid bone healing of spinal fusions. The FDA has awarded ZetaFuse™ Breakthrough Device Designation for the complete spinal column.
ZetaSet™ is the first synthetic, osteo-inductive, biologic designed specifically for the treatment of osteoporotic fractures, high energy injuries with bone defects, and for patients with fractures of the tibial plateau (knee) and plafond (ankle).
ZetaBase™ is an osteo-conductive and osteo-promotive therapy, intended for the use as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. Pending 510K approval Q4 2021.
ZetaDent™ is an osteo-inductive biologic intended to promote bone formation as a part of localized ridge augmentation procedures prior to dental implant placement, alveolar ridge reconstruction procedures for prosthetic treatment, and for filling of bone defects in the oral cavity.
Pending FDA/HC Spine Met Tumor Study Anticipated Late Q4 2021